Business / Finance

RSS

Scil Proteins concludes financing round with BioNet Holding for €24 million

Scil Proteins today announced that it has concluded a financing round with its existing investor, BioNet Holding, worth €24 million. The funds are intended to finance the development of two products derived from the Company's Affilin platform into clinical Phase I over the next three years.

2 Feb 2011

Elsevier acquires Cancer Information Group's oncology journals portfolio

Elsevier, the leading global publisher of scientific, technical, and medical information products and services, announced today that it acquired the oncology portfolio of journals previously published by CIG Media Group LP., (operated as Cancer Information Group).

2 Feb 2011

Thermo Fisher Scientific 2010 revenues increase 7% to $10.79 billion

Thermo Fisher Scientific Inc., the world leader in serving science, today reported its financial results for the fourth quarter and full year ended December 31, 2010.

From Thermo Fisher Scientific Inc. 2 Feb 2011

Boston Scientific fourth quarter net sales decrease 4% to $2.002 billion

Boston Scientific Corporation today announced financial results for the fourth quarter and full year ended December 31, 2010, as well as net sales and earnings per share (EPS) guidance for the full year and first quarter 2011.

2 Feb 2011

Boston-based Research 2.0 begins Viral Genetics coverage, publishes initial report

Boston-based Research 2.0 initiated coverage of Viral Genetics, Inc, and published their initial report today. The report is available on the company's website at www.viralgenetics.com/investors/press-releases/R20Report and is also distributed over the internet and through institutional platforms including FactSet, CapitalIQ, and TheMarkets.com.

2 Feb 2011

Intrexon announces AgBio Division launch and Agarigen acquisition

Intrexon Corporation, a next generation synthetic biology company, today announced the launch of its Agricultural Biotechnology (AgBio) Division in Research Triangle Park, North Carolina and the acquisition of Agarigen, Inc., a North Carolina-based company that has developed a novel, mushroom-based expression platform for the rapid, high yield production of recombinant proteins.

2 Feb 2011

Pfizer board authorizes new $5 billion share repurchase program

Pfizer Inc. today announced that its board of directors authorized a new share repurchase program of up to $5 billion of its common stock. This is in addition to approximately $4 billion of authorization remaining under its current repurchase program and increases the company's total repurchase authorization to $9 billion.

2 Feb 2011

Seattle Genetics to sell common stock in underwritten public offering

Seattle Genetics, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the shares in the offering are to be sold by Seattle Genetics.

1 Feb 2011

Genzyme's diagnostic products sold to Sekisui Chemical for $265 million

Genzyme Corporation today announced that it has completed the sale of its diagnostic products business to Sekisui Chemical Co., Ltd. for $265 million in cash.

1 Feb 2011

OPKO Health acquires CURNA

OPKO Health, has acquired CURNA, a privately held company based in Jupiter, Florida, engaged in the discovery of new drugs for the treatment of a wide variety of illnesses, such as cancer, heart disease, metabolic disorders and genetic anomalies.

1 Feb 2011

Savient announces pricing of $200 million 4.75% Convertible Senior Notes due 2018

Savient Pharmaceuticals, Inc. announced it has priced $200 million aggregate principal amount of 4.75% Convertible Senior Notes due 2018 (the "Notes") pursuant to an automatically effective registration statement filed with the Securities and Exchange Commission on January 31, 2011. In addition, Savient has granted the underwriters an option to purchase up to an additional $30 million aggregate principal amount of Notes, solely to cover over-allotments.

1 Feb 2011

Kensey Nash second quarter revenue decreases to $17.4 million

Kensey Nash Corporation, a medical device company primarily focused on regenerative medicine for a wide range of medical procedures, today reported the results for its second quarter ended December 31, 2010.

1 Feb 2011

Biogen Idec 2010 total revenues increase 8% to $4.7 billion

Biogen Idec Inc., a global biotechnology leader in the discovery, development, manufacturing, and commercialization of innovative therapies, today announced its full year and fourth quarter 2010 results.

1 Feb 2011

RTI fourth quarter net sales increases to $114.7 million

RTI International Metals, Inc.,, released results today for the fourth quarter and full year of 2010.

1 Feb 2011

Kinetic Concepts fourth quarter net earnings increase 12% to $74.0 million

Kinetic Concepts, Inc. today reported fourth quarter and full year 2010 total revenue of $527.5 million and $2.02 billion, respectively, compared to $526.8 million and $1.99 billion in the corresponding periods of the prior year.

1 Feb 2011

CorVel third quarter earnings per share increases 4% to $0.56

CorVel Corporation today announced earnings per share of $0.56 for the quarter ended December 31, 2010, a 4% increase compared to $0.54 in the same quarter of the prior fiscal year. Earnings per share for the nine months ended December 31, 2010 were $1.82, a 20% increase over the $1.52 earnings per share for the nine months ended December 31, 2009.

1 Feb 2011

Covidien first-quarter net sales increase 5% to $2.77 billion

Covidien plc today reported results for the first quarter of fiscal 2011 (October-December 2010). First-quarter net sales of $2.77 billion increased 5% from the $2.64 billion reported a year ago. Foreign exchange rate movement had no impact on the quarterly sales growth rate.

1 Feb 2011

Genzyme, Sanofi-Aventis enter confidentiality agreement

Genzyme Corp. announced today that ongoing discussions with Sanofi-Aventis have progressed to the point where Genzyme's board has authorized the company to enter into a confidentiality agreement with Sanofi-Aventis in order to allow Sanofi to conduct due diligence. Discussions between Genzyme's advisors and Sanofi's advisors and between Genzyme and Sanofi representatives are continuing.

1 Feb 2011

Court rules in favor of Volcano/Axsun against LightLab Imaging

Volcano Corporation said today that the Superior Court of Massachusetts has issued a decision that ruled in favor of Volcano and its wholly-owned subsidiary Axsun Technologies, Inc., and against LightLab Imaging, Inc., on all of LightLab's remaining claims for trade secret misappropriation. The 11-page decision also rejected LightLab's request for injunctive relief.

1 Feb 2011

Masimo amends January 2006 settlement agreement with Covidien

Following today's announcement by Masimo that the company has amended its January 2006 settlement agreement with Covidien, Masimo provides the following additional information.

1 Feb 2011